Analysis of spatial atlas of ADC targets in immunotherapy-treated NSCLC to link compartment-specific target expression with tumor immune contexture, clinical outcome, and on-treatment remodeling.
Prof. Antoine Italiano (Gustave Roussy) delivered this oral presentation: I was honored to present our work on an integrated spatial ADC target atlas across NSCLC, bladder, gastric and endometrial cancers. Using multiplex immunofluorescence, proteomics and immune-contexture analyses, we aimed to move beyond single-marker prevalence and better understand target coverage, co-expression, spatial heterogeneity and immune geography. […]
Tumor-cell NY-ESO-1 Expression Predicts Poor Response to PD-1/PD-L1 Blockade in NSCLC
Background & rationale NY-ESO-1 is an immunogenic cancer-testis antigen and a therapeutic target for TCR-based strategies. Its value as a baseline biomarker for PD-1/PD-L1 blockade in NSCLC remains poorly defined. Because NY-ESO-1 is biologically relevant only when expressed by tumor epithelial cells, this study focused on CK7+/NY-ESO-1+ tumor cells. Study design Cohort 190 baseline FFPE […]
How ADORA2B drives metastasis in pleomorphic sarcoma — and why it’s a tractable target
High-Dimensional Spatial Profiling of the Tumor Immune Microenvironment (TME) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Predictive Biomarkers of Immunotherapy
HNSCC remains a challenging malignancy, with only a subset of patients benefiting from PD-1/PD-L1 blockade immunotherapy. Despite clinical advances, reliable predictive biomarkers to guide patient selection and improve outcomes are urgently needed. Current strategies often rely on PD-L1 expression or tumor mutational burden, but these lack sufficient specificity and sensitivity. The aim of the study […]
How normal-appearing vitiligo skin keeps its pigment: PD-1 and regulatory T cells restrain disease-ready CD8 T cells
How an engineered CD40 antibody, injected into tumors, builds the immune structures that drive whole-body cancer responses
How regorafenib plus avelumab reshapes the immune microenvironment of “cold” soft-tissue sarcomas — and why response stays elusive
CCR8 positive Tregs and Their Correlation with Immunotherapy Response in Advanced Non-Small Cell Lung Cancer (NSCLC)
The chemokine receptor CCR8 is selectively expressed on activated regulatory T cells (Tregs), which are recognized as potent immunosuppressive modulators within the tumor microenvironment. Several clinical trials are currently evaluating the therapeutic benefit of selectively depleting these cells to enhance the efficacy of immune checkpoint inhibitors (ICIs). However, the prognostic and predictive value of activated […]
Impact of Immune Contexture on Immunotherapy Response in NSCLC: Insights from Multiplex IHC and Machine Learning-Based Phenotyping
Predicting which NSCLC patients will benefit from immunotherapy requires more than measuring a single biomarker. Our previous work has helped show that key spatial features of the tumor microenvironment—such as mature tertiary lymphoid structures (Nature Cancer, 2021; Cell Reports Medicine, 2025) and macrophage infiltration within the tumor compartment (Journal for ImmunoTherapy of Cancer, 2022)—are closely associated with treatment outcome. Building […]
Enhanced anti-tumor response to anti-angiogenic / hypoxia-regulating therapies in combination with immune checkpoint blockade in a murine model of renal carcinoma
Background Antiangiogenic and other targeted therapies have shown efficacy in both preclinical and clinical settings. However, tumors can acquire resistance, allowing them to survive and grow under hypoxic conditions. In this context, combining angiogenesis- and/or hypoxia-targeted strategies with immune checkpoint inhibitors, such as anti-PD1 or anti-PDL1 antibodies, is of particular interest. These therapeutic combinations may […]